Biosimilar Makers Take On ‘Huge’ Barriers To A Sustainable European Market

Biosimilar industry leaders are gearing up to tackle the threats to the longer-term sustainability of the sector caused by divergences in biosimilar usage across Europe, a dearth of near-term biologic expiries, and a shift towards smaller patient populations. But they say the industry cannot solve these problems on its own, and later this year they will be pushing the new European Parliament and European Commission to look afresh at ways to promote a competitive and sustainable market. 

In a wide-ranging interview with the Pink Sheet during last week’s Medicines for Europe biosimilars conference in Amsterdam, Adrian van den Hoven and Marc-Alexander Mahl, the association’s director general and...